Companies

Search, filter and compare every US company we cover.

Search companies

Sector

Industry

Size

Today

Profitable Growing

Add filter

Clear all

Revenue growth

Min % Max %

215 companies match

Company	Industry	Market cap	Price	Day change	Revenue	Revenue growth	Operating margin	P/E	5-yr growth	Gross margin	Net margin	Free cash flow	FCF margin	Return on capital	Return on equity	Net debt	Net debt / EBITDA	Dividends + buybacks	Share count change	F-score	Insider buys (90d)	Insider sales (90d)
Eli LillyLLY	Pharmaceuticals	$1.14T	$1,273.46	2.5%	$65.2B	44.7%	—	42.7x	21.6%	83.0%	31.7%	$9.0B	13.8%	40.8%	101.2%	$33.6B	1.2x	$9.5B	−0.5%	8	$0.0M	$16.0M
BeOne Medicines Ltd.ONC	Pharmaceutical Preparations	$568.5B	$377.63	1.2%	$5.3B	40.2%	8.4%	—	76.8%	87.5%	5.4%	$942M	17.6%	46.7%	7.5%	−$3.7B	−6.3x	—	7.8%	8	$0.0M	$0.0M
Intuitive SurgicalISRG	Health Care Equipment	$159.0B	$452.29	1.9%	$10.1B	20.5%	29.3%	54.8x	18.2%	66.0%	28.4%	$2.5B	24.8%	20.9%	16.7%	−$5.9B	−1.7x	$2.3B	0.2%	5	$0.0M	$4.8M
Natera, Inc.NTRA	Services-Medical Laboratories	$57.9B	$403.95	0.6%	$2.3B	35.9%	−13.4%	—	42.6%	—	−9.0%	$109M	4.7%	−34.2%	−14.3%	−$996M	—	—	9.6%	4	$0.0M	$0.0M
Alnylam Pharmaceuticals, Inc.ALNY	Pharmaceutical Preparations	$31.0B	$224.03	1.4%	$3.7B	65.2%	13.5%	96.2x	49.8%	81.8%	8.4%	$465M	12.5%	—	73.3%	—	—	—	5.5%	5	$0.0M	$0.0M
IncyteINCY	Biotechnology	$23.9B	$115.71	1.0%	$5.1B	21.2%	29.5%	16.3x	14.0%	92.8%	25.0%	$1.4B	26.4%	79.4%	29.9%	−$3.5B	−2.2x	$0.0M	−4.7%	8	$0.0M	$15.0M
Guardant Health, Inc.GH	Services-Medical Laboratories	$22.5B	$169.08	3.8%	$982M	32.9%	−44.5%	—	27.9%	64.5%	−42.4%	−$233M	−23.7%	−170.1%	—	$302M	—	$45.0M	2.1%	5	$0.0M	$0.0M
INSMED IncINSM	Pharmaceutical Preparations	$20.3B	$93.39	1.8%	$606M	66.7%	−205.6%	—	29.8%	79.7%	−210.5%	−$968M	−159.6%	—	−249.3%	−$859M	—	—	21.3%	4	$0.0M	$0.0M
HalozymeHALO	Biotechnology	$15.2B	$125.63	0.9%	$1.4B	37.6%	33.6%	36.6x	39.2%	83.6%	22.7%	$645M	46.2%	19.2%	153.6%	$2.0B	4.2x	$342M	−4.3%	5	$0.0M	$14.9M
Neurocrine BiosciencesNBIX	Biotechnology	$14.9B	$142.70	0.4%	$2.9B	21.5%	21.6%	20.9x	22.3%	98.2%	16.7%	$749M	26.2%	25.6%	16.4%	−$1.5B	−2.3x	$168M	−1.2%	6	$0.0M	$1.1M
BridgeBio Pharma, Inc.BBIO	Pharmaceutical Preparations	$13.4B	$68.56	0.6%	$502M	126.3%	−104.2%	—	127.4%	95.8%	−146.0%	−$447M	−89.0%	—	—	$1.4B	—	$48.3M	2.9%	2	$0.0M	$0.0M
BrightSpring Health ServicesBTSG	Health Care Services	$13.2B	$60.11	1.2%	$12.9B	28.2%	2.3%	36.2x	—	11.8%	1.5%	$395M	3.1%	5.3%	10.8%	$2.4B	5.3x	$43.2M	13.9%	7	$0.0M	$0.9M
Madrigal Pharmaceuticals, Inc.MDGL	Pharmaceutical Preparations	$12.7B	$434.24	4.2%	$958M	432.1%	−31.3%	—	—	—	−30.1%	−$190M	−19.8%	—	−42.5%	−$644M	—	—	5.6%	3	$0.0M	$0.0M
GlaukosGKOS	Health Care Equipment	$10.5B	$178.88	1.2%	$507M	32.3%	−39.3%	—	17.7%	55.7%	−37.0%	−$22.5M	−4.4%	—	−26.4%	—	—	$0.0M	8.4%	—	$0.0M	$17.9M
InsuletPODD	Health Care Equipment	$10.3B	$149.01	0.6%	$2.7B	30.7%	17.5%	27.9x	24.5%	71.6%	9.1%	$378M	14.0%	20.4%	18.1%	$233M	0.4x	$59.6M	−2.7%	7	$0.2M	$0.0M
Oscar HealthOSCR	Managed Health Care	$10.3B	$30.99	7.0%	$11.7B	27.5%	−3.4%	23.8x	90.8%	—	−3.8%	$1.1B	9.1%	—	−44.5%	−$3.6B	—	$0.0M	−1.3%	4	$0.0M	$26.8M
Krystal BiotechKRYS	Biotechnology	$9.6B	$311.50	2.7%	$389M	33.9%	41.5%	39.0x	—	—	52.6%	$189M	48.6%	43.6%	18.9%	−$828M	−5.0x	$0.0M	0.7%	5	$0.0M	$26.2M
Caris Life Sciences, Inc.CAI	Services-Medical Laboratories	$9.1B	$32.00	0.9%	$812M	97.0%	5.6%	3.8x	—	—	−8.4%	$66.9M	8.2%	22.7%	—	−$420M	−6.2x	$0.1M	371.0%	5	$0.0M	$0.0M
Twist Bioscience CorpTWST	Biological Products, (No Diagnostic Substances)	$8.7B	$139.92	3.3%	$377M	20.3%	−36.2%	—	33.1%	50.7%	−20.6%	−$75.6M	−20.1%	—	−16.4%	—	—	—	3.1%	4	$0.0M	$0.0M
ImmunityBio, Inc.IBRX	Biological Products, (No Diagnostic Substances)	$8.6B	$8.22	1.1%	$113M	668.3%	−226.0%	—	184.8%	99.3%	−310.2%	−$309M	−272.6%	—	—	−$241M	—	—	31.3%	4	$0.0M	$0.0M
Tg Therapeutics, Inc.TGTX	Pharmaceutical Preparations	$8.5B	$54.17	1.9%	$616M	87.3%	20.0%	19.8x	426.7%	83.7%	72.6%	−$25.0M	−4.1%	16.4%	102.8%	$104M	0.8x	—	0.7%	4	$0.0M	$0.0M
Arrowhead PharmaceuticalsARWR	Biotechnology	$8.3B	$58.02	0.6%	$829M	23,258.2%	11.9%	—	56.6%	—	−0.2%	$157M	18.9%	—	−0.5%	−$665M	−5.5x	$0.0M	11.7%	5	$0.0M	$1.2M
PACS Group, Inc.PACS	Services-Skilled Nursing Care Facilities	$7.7B	$47.64	0.3%	$5.3B	29.3%	5.9%	27.9x	—	—	3.6%	—	—	18.9%	23.1%	$312M	—	$0.0M	5.5%	7	$0.0M	$0.0M
Axsome Therapeutics, Inc.AXSM	Pharmaceutical Preparations	$7.5B	$145.04	7.1%	$638M	65.5%	−26.1%	—	—	—	−28.7%	−$93.9M	−14.7%	—	−252.1%	−$128M	—	—	3.8%	4	$0.0M	$0.0M
Ionis Pharmaceuticals IncIONS	Pharmaceutical Preparations	$7.1B	$42.93	2.2%	$944M	33.8%	−40.4%	—	5.3%	98.3%	−40.4%	−$320M	−33.9%	—	−70.8%	−$865M	—	—	7.0%	3	$0.0M	$0.0M
Ligand PharmaceuticalsLGND	Biotechnology	$6.6B	$303.53	1.4%	$268M	60.4%	15.3%	32.3x	10.4%	—	46.4%	$48.9M	18.2%	4.9%	13.5%	−$287M	−3.8x	$15.0M	11.0%	5	$0.0M	$14.6M
Hims & Hers HealthHIMS	Health Care Services	$6.4B	$27.71	4.9%	$2.3B	59.0%	4.5%	—	73.6%	73.8%	5.5%	$57.4M	2.5%	19.0%	25.2%	$395M	2.5x	$90.0M	9.1%	4	$0.0M	$3.8M
Kiniksa Pharmaceuticals International, plcKNSA	Pharmaceutical Preparations	$6.3B	$76.73	5.0%	$678M	60.1%	11.4%	84.3x	—	88.5%	8.7%	$136M	20.1%	—	11.7%	—	—	—	10.6%	7	$0.0M	$0.0M
Rhythm Pharmaceuticals, Inc.RYTM	Pharmaceutical Preparations	$6.1B	$89.27	1.8%	$190M	45.8%	−101.2%	—	—	89.7%	−103.6%	−$117M	−61.5%	—	−244.5%	−$281M	—	—	6.5%	6	$0.0M	$0.0M
BillionToOne, Inc.BLLN	Services-Medical Laboratories	$5.9B	$107.77	2.0%	$305M	100.0%	5.3%	103.6x	—	68.3%	2.4%	$15.7M	5.2%	37.2%	6.5%	−$438M	−19.1x	$0.0M	110.6%	7	$0.0M	$0.0M
Ptc Therapeutics, Inc.PTCT	Pharmaceutical Preparations	$5.6B	$60.59	3.9%	$1.7B	114.5%	50.1%	—	35.4%	—	39.4%	$702M	40.6%	—	—	−$1.7B	−1.8x	—	14.9%	6	$0.0M	$0.0M
CG Oncology, Inc.CGON	Biological Products, (No Diagnostic Substances)	$5.4B	$61.71	1.3%	$4.0M	254.7%	−4,722.1%	—	—	—	−3,985.0%	−$132M	−3,279.2%	−1,120.8%	−21.7%	−$739M	—	—	23.7%	2	$0.0M	$0.0M
Mirum Pharmaceuticals, Inc.MIRM	Pharmaceutical Preparations	$5.1B	$80.39	3.3%	$521M	54.7%	−4.2%	—	—	—	−4.5%	$54.9M	10.5%	—	−8.6%	—	—	—	5.6%	4	$0.0M	$0.0M
Heartflow, Inc.HTFL	Surgical & Medical Instruments & Apparatus	$4.9B	$56.71	2.3%	$176M	39.9%	−36.4%	18.7x	—	76.8%	−66.3%	−$59.0M	−33.5%	—	—	—	—	—	587.1%	4	$0.0M	$0.0M
Travere Therapeutics, Inc.TVTX	Pharmaceutical Preparations	$4.7B	$50.08	4.5%	$491M	110.5%	−12.8%	—	19.9%	97.9%	−5.2%	—	—	—	−29.4%	—	—	—	13.1%	6	$0.0M	$0.0M
Liquidia CorpLQDA	Pharmaceutical Preparations	$4.3B	$42.65	7.5%	$158M	1,031.2%	−32.5%	30.5x	192.5%	—	−43.5%	−$40.0M	−25.3%	—	−111.1%	—	—	—	9.3%	3	$0.0M	$0.0M
Arcutis Biotherapeutics, Inc.ARQT	Pharmaceutical Preparations	$4.2B	$31.20	3.1%	$376M	91.3%	−3.3%	141.8x	—	90.2%	−4.3%	−$6.3M	−1.7%	−12.5%	−9.3%	−$112M	—	—	5.2%	4	$0.0M	$0.0M
DBV Technologies S.A.DBVT	Biological Products, (No Diagnostic Substances)	$4.2B	$9.75	0.7%	$5.6M	35.8%	−2,609.2%	—	−13.0%	—	−2,607.3%	−$122M	−2,159.6%	—	−149.8%	—	—	—	43.9%	3	$0.0M	$0.0M
Adaptive Biotechnologies CorpADPT	Biological Products, (No Diagnostic Substances)	$4.1B	$25.51	4.5%	$277M	54.8%	−20.6%	—	23.0%	74.2%	−21.5%	−$48.9M	−17.7%	−36.7%	−28.2%	−$95.8M	—	—	3.1%	5	$0.0M	$0.0M
iRhythm Holdings, Inc.IRTC	Surgical & Medical Instruments & Apparatus	$4.0B	$121.27	1.4%	$747M	26.2%	−7.7%	—	23.0%	70.6%	−6.0%	$34.5M	4.6%	—	−36.6%	—	—	$0.0M	2.6%	5	$0.0M	$0.0M
AbCellera Biologics Inc.ABCL	Pharmaceutical Preparations	$3.6B	$11.82	4.0%	$75.1M	160.6%	−289.0%	—	−20.3%	—	−194.9%	−$174M	−231.7%	—	−14.5%	—	—	—	1.5%	4	$0.0M	$0.0M
Tango Therapeutics, Inc.TNGX	Pharmaceutical Preparations	$3.5B	$23.34	16.4%	$62.4M	48.3%	−178.4%	—	52.1%	—	−162.9%	−$140M	−224.3%	—	−37.2%	—	—	—	6.4%	3	$0.0M	$0.0M
IDEAYA Biosciences, Inc.IDYA	Pharmaceutical Preparations	$3.2B	$34.71	3.9%	$219M	3,024.4%	−72.8%	—	62.1%	—	−52.0%	−$73.5M	−33.6%	—	−10.9%	—	—	—	8.3%	3	$0.0M	$0.0M
Aveanna Healthcare Holdings, Inc.AVAH	Services-Home Health Care Services	$3.0B	$13.38	0.5%	$2.4B	20.2%	10.5%	10.6x	10.2%	33.3%	9.2%	—	—	19.7%	634.7%	$1.1B	4.1x	—	11.4%	6	$0.0M	$0.0M
Tarsus Pharmaceuticals, Inc.TARS	Biological Products, (No Diagnostic Substances)	$3.0B	$68.20	5.4%	$451M	146.7%	−15.7%	—	—	—	−14.7%	−$22.3M	−4.9%	—	−23.4%	−$345M	—	—	11.1%	4	$0.0M	$0.0M
Privia Health Group, Inc.PRVA	Services-Health Services	$3.0B	$22.41	2.1%	$2.1B	22.3%	1.6%	101.9x	21.0%	—	1.1%	—	—	—	3.3%	—	—	—	2.6%	5	$0.0M	$0.0M
Nurix Therapeutics, Inc.NRIX	Pharmaceutical Preparations	$2.9B	$25.34	0.7%	$84.0M	54.0%	−340.2%	11.0x	36.3%	—	−314.9%	−$263M	−313.7%	—	−49.6%	—	—	—	29.1%	3	$0.0M	$0.0M
TransMedics Group, Inc.TMDX	Electromedical & Electrotherapeutic Apparatus	$2.9B	$70.74	1.8%	$605M	37.1%	17.9%	18.3x	88.2%	59.9%	31.4%	$134M	22.1%	—	54.2%	−$479M	−3.5x	—	15.1%	6	$0.0M	$0.0M
Precigen, Inc.PGEN	Pharmaceutical Preparations	$2.6B	$6.19	3.1%	$9.7M	146.7%	−1,141.1%	—	−21.3%	—	−2,588.2%	−$89.8M	−927.6%	−538.0%	−843.6%	−$4.7M	—	—	16.9%	2	$0.0M	$0.0M
Beam Therapeutics Inc.BEAM	Biological Products, (No Diagnostic Substances)	$2.5B	$24.05	2.1%	$140M	120.0%	−274.6%	—	466.3%	—	−57.2%	−$360M	−257.7%	—	−8.1%	—	—	—	20.2%	3	$0.0M	$0.0M

What do these columns mean?

Market cap: Last close times the latest diluted share count, so it is approximate.
Price: Closing share price on the last trading day.
Day change: Change in the closing price against the previous trading day's close.
Revenue: Total sales reported in the income statement.
Revenue growth: Change in revenue against the year (or quarter) a year earlier.
Operating margin: Operating income as a share of revenue.
P/E: Last close divided by diluted earnings per share over the last four quarters.
5-yr growth: Revenue growth a year, compounded over the last five years.
Gross margin: Gross profit as a share of revenue.
Net margin: Net income as a share of revenue.
Free cash flow: Cash from operations minus capital spending.
FCF margin: Free cash flow as a share of revenue.
Return on capital: After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on equity: Net income as a share of average shareholders' equity.
Net debt: Debt and finance leases minus cash and short-term investments. Negative means net cash.
Net debt / EBITDA: Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
Dividends + buybacks: Cash returned to shareholders through dividends and share repurchases.
Share count change: Change in the diluted share count. Negative means buybacks shrank it.
F-score: Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
Industry: The industry the company reports under, from its SEC filing code. Click it to see its peers.
Colours and dashes: Green is up or growing, red is down or shrinking. — means no data, or a P/E that is not meaningful (losses, or above 200).
Units: M = millions, B = billions, T = trillions, in USD. Fundamentals use the latest fiscal year. Use “Edit columns” to show more figures, hide some or change their order.